|
Name |
Lithocarin B
|
Molecular Formula | C28H40O6 | |
IUPAC Name* |
[(1R,2R,7S,8aR)-1,8a-dimethyl-6-oxo-7-prop-1-en-2-yl-1,2,3,4,7,8-hexahydronaphthalen-2-yl] (4E,6E)-9-acetyloxy-3-hydroxy-2-methyldeca-4,6-dienoate
|
|
SMILES |
C[C@H]1[C@@H](CCC2=CC(=O)[C@@H](C[C@]12C)C(=C)C)OC(=O)C(C)C(/C=C/C=C/CC(C)OC(=O)C)O
|
|
InChI |
InChI=1S/C28H40O6/c1-17(2)23-16-28(7)20(5)26(14-13-22(28)15-25(23)31)34-27(32)19(4)24(30)12-10-8-9-11-18(3)33-21(6)29/h8-10,12,15,18-20,23-24,26,30H,1,11,13-14,16H2,2-7H3/b9-8+,12-10+/t18?,19?,20-,23-,24?,26+,28+/m0/s1
|
|
InChIKey |
JHCPVFZPASTLDV-CKEAXHSXSA-N
|
|
Synonyms |
Lithocarin B
|
|
CAS | NA | |
PubChem CID | 146683442 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 472.6 | ALogp: | 5.0 |
HBD: | 1 | HBA: | 6 |
Rotatable Bonds: | 11 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 89.9 | Aromatic Rings: | 2 |
Heavy Atoms: | 34 | QED Weighted: | 0.28 |
Caco-2 Permeability: | -4.611 | MDCK Permeability: | 0.00001330 |
Pgp-inhibitor: | 0.945 | Pgp-substrate: | 0.338 |
Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.011 |
30% Bioavailability (F30%): | 0.138 |
Blood-Brain-Barrier Penetration (BBB): | 0.688 | Plasma Protein Binding (PPB): | 80.88% |
Volume Distribution (VD): | 0.341 | Fu: | 15.09% |
CYP1A2-inhibitor: | 0.051 | CYP1A2-substrate: | 0.077 |
CYP2C19-inhibitor: | 0.341 | CYP2C19-substrate: | 0.832 |
CYP2C9-inhibitor: | 0.26 | CYP2C9-substrate: | 0.968 |
CYP2D6-inhibitor: | 0.599 | CYP2D6-substrate: | 0.767 |
CYP3A4-inhibitor: | 0.882 | CYP3A4-substrate: | 0.693 |
Clearance (CL): | 3.527 | Half-life (T1/2): | 0.411 |
hERG Blockers: | 0.003 | Human Hepatotoxicity (H-HT): | 0.719 |
Drug-inuced Liver Injury (DILI): | 0.902 | AMES Toxicity: | 0.101 |
Rat Oral Acute Toxicity: | 0.446 | Maximum Recommended Daily Dose: | 0.1 |
Skin Sensitization: | 0.864 | Carcinogencity: | 0.845 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.016 |
Respiratory Toxicity: | 0.351 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004128 | 0.750 | D0X4RS | 0.250 | ||||
ENC003665 | 0.670 | D02CJX | 0.248 | ||||
ENC003895 | 0.626 | D0W5LS | 0.236 | ||||
ENC004660 | 0.611 | D0G7KJ | 0.235 | ||||
ENC002230 | 0.500 | D09WYX | 0.234 | ||||
ENC001526 | 0.417 | D0X2LV | 0.232 | ||||
ENC002137 | 0.385 | D08TEJ | 0.230 | ||||
ENC003292 | 0.324 | D0FG6M | 0.230 | ||||
ENC003293 | 0.319 | D00AEQ | 0.229 | ||||
ENC005061 | 0.309 | D08BDT | 0.227 |